Comparative Pharmacology
Head-to-head clinical analysis: NORTREL 1 35 21 versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTREL 1 35 21 versus TAYTULLA.
NORTREL 1/35-21 vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
One capsule orally once daily for 24 weeks.
None Documented
None Documented
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive